Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 13, 2019

Vaximm partners with NEC on neoantigen cancer vaccines

Biotech company Vaximm has partnered with technologies provider NEC Corporation to develop personalised neoantigen cancer vaccines.

Biotech company Vaximm has partnered with technologies provider NEC Corporation to develop personalised neoantigen cancer vaccines.

The companies signed strategic clinical trial collaboration and equity investment agreements. As part of the collaboration agreement, NEC will fund a Phase I clinical trial.

Vaximm and NEC will use T-cell immunotherapy technology and artificial intelligence (AI) technology to create the vaccines.

NEC OncoImmunity’s bioinformatics pipelines use NEC’s AI technology as a neoantigen prediction system.

Furthermore, Vaximm’s product platform builds on a live attenuated, orally available bacterial vaccine strain, modified to induce cytotoxic T-cells to target specific tumour structures.

Vaximm chief operating officer and co-founder Heinz Lubenau said: “NEC’s novel AI technology will enable not only the identification but also the prioritisation of neoantigens from each patient, facilitating the optimal potential treatment for each individual.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

“Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalised vaccine. Individualised therapy is at the cutting edge of cancer treatment today, and, with this collaboration, we are able to further contribute to this approach.”

A Phase I clinical trial, to treat various solid tumours, will be launched next year and performed by Vaxxim.

NEC holds an option for rights to develop and commercialise the programme in global markets, excluding China and other Asian regions outside of Japan.

Currently, Vaximm’s portfolio includes VXM01, an oral candidate designed to stimulate killer cells to target tumour-specific vasculature, as well as some immune-suppressive cells.

Various cancer types, including brain cancer, are the focus of the candidate. The company is also working on a pre-clinical neoantigen programme.

Vaximm has an agreement with China Medical System (CMS), providing complete rights in China and other Asian countries, excluding Japan, for its existing programmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU